MedTrace Logo

RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors

NCT00576680 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2020-07-09

Study results available
· View outcomes & findings →

Summary

This research study will test the safety of RAD001 in combination with temozolomide.

Conditions

  • Pancreatic Neuroendocrine Tumor

Interventions

DRUG

RAD001

Given orally once a day

DRUG

Temozolomide

Taken orally once a day for one week followed by a one-week break period

Sponsors & Collaborators

Principal Investigators

  • Jennifer Chan, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2019-03-29
Completion
2019-03-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00576680 on ClinicalTrials.gov